Refractory Kasabach–Merritt phenomenon successfully treated with sirolimus, and a mini‐review of the published work

Publisher: John Wiley & Sons Inc

E-ISSN: 1346-8138|42|4|401-404

ISSN: 0385-2407

Source: THE JOURNAL OF DERMATOLOGY, Vol.42, Iss.4, 2015-04, pp. : 401-404

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

AbstractKasabach–Merritt phenomenon (KMP) is a rare and life‐threatening disease involving a vascular tumor combined with severe consumptive coagulopathy. We present for the first time a case of KMP with the vascular tumor involving two anatomical sites; the patient failed to respond to steroids and vincristine. Following sirolimus therapy at a dose of 0.8 mg/m2 twice daily, the lesions shrank and the platelet count improved and remained normal 4 months after initial therapy. Current treatments for KMP are not particularly effective. Sirolimus at 0.8 mg/m2 per dose, administrated twice daily, appears to be a safe and effective management option. It appears to be an interesting therapeutic option in refractory KMP, but the time to response is variable.